KNSA

SEC source: 0001415889-24-028844 · form4-12102024_091222.xml · derivative · entry 6

Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,552

Underlying: Class A Ordinary Share · 18,860 shares

Expires 2032-04-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024.

F5 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 8, 2022.

SEC source: 0001415889-24-028844 · form4-12102024_091222.xml · nonDerivative · entry 4

Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,958

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024.

F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $21.25 and $21.755. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001415889-24-028844 · form4-12102024_091222.xml · nonDerivative · entry 3

Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 41,818

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024.

SEC source: 0001415889-24-028844 · form4-12102024_091222.xml · derivative · entry 5

Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,528

Underlying: Class A Ordinary Share · 2,406 shares

Expires 2033-03-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024.

F4 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 2, 2023.

SEC source: 0001415889-24-028844 · form4-12102024_091222.xml · nonDerivative · entry 2

Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,958

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024.

F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $21.25 and $21.31. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001415889-24-028844 · form4-12102024_091222.xml · nonDerivative · entry 1

Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,364

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024.

SEC source: 0001415889-24-028431 · form4-12062024_121225.xml · derivative · entry 9

Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,934

Underlying: Class A Ordinary Shares · 1,123 shares

Expires 2033-03-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024.

F5 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 2, 2023.

SEC source: 0001415889-24-028431 · form4-12062024_121225.xml · nonDerivative · entry 6

Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,958

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024.

F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $21.25 and $21.265. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001415889-24-028431 · form4-12062024_121225.xml · nonDerivative · entry 5

Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,081

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024.

SEC source: 0001415889-24-028431 · form4-12062024_121225.xml · derivative · entry 8

Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 28,057

Underlying: Class A Ordinary Share · 5,024 shares

Expires 2033-03-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024.

F5 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 2, 2023.

SEC source: 0001415889-24-028431 · form4-12062024_121225.xml · nonDerivative · entry 4

Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,958

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024.

F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $21.25 and $21.265. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001415889-24-028431 · form4-12062024_121225.xml · nonDerivative · entry 3

Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,982

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024.

SEC source: 0001415889-24-028431 · form4-12062024_121225.xml · derivative · entry 7

Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,081

Underlying: Class A Ordinary Share · 8,969 shares

Expires 2033-03-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024.

F5 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 2, 2023.

SEC source: 0001415889-24-028431 · form4-12062024_121225.xml · nonDerivative · entry 2

Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,958

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024.

F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $21.26 and $21.70. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001415889-24-028431 · form4-12062024_121225.xml · nonDerivative · entry 1

Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,927

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024.

SEC source: 0001415889-24-027993 · form4-12022024_091211.xml · derivative · entry 6

Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,814

Underlying: Class A Ordinary Share · 9 shares

Expires 2032-04-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024.

F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 7, 2022.

SEC source: 0001415889-24-027993 · form4-12022024_091211.xml · nonDerivative · entry 4

Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,528

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024.

SEC source: 0001415889-24-027993 · form4-12022024_091211.xml · nonDerivative · entry 3

Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,537

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024.

SEC source: 0001415889-24-027993 · form4-12022024_091211.xml · derivative · entry 5

Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,823

Underlying: Class A Ordinary Share · 8,637 shares

Expires 2032-04-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024.

F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 7, 2022.

SEC source: 0001415889-24-027993 · form4-12022024_091211.xml · nonDerivative · entry 2

Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,528

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024.

F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $22.45 and $22.465. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001415889-24-027993 · form4-12022024_091211.xml · nonDerivative · entry 1

Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,165

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024.

SEC source: 0001415889-24-027354 · form4-11202024_091114.xml · derivative · entry 3

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,017

Underlying: Class A Ordinary Share · 10,000 shares

Expires 2025-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.

F3 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001415889-24-027354 · form4-11202024_091114.xml · nonDerivative · entry 2

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 102,975

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.

F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $20.685 and $21.505. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001415889-24-027354 · form4-11202024_091114.xml · nonDerivative · entry 1

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 119,975

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.

SEC source: 0001415889-24-026617 · form4-11122024_091100.xml · derivative · entry 3

Levy Richard S · CIK 0001454983 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Ordinary Shares · 1,303 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

F2 · derivative.exercise_date: The RSUs vested immediately upon grant on November 7, 2024; there was no expiration date for the RSUs.

F2 · derivative.expiration_date: The RSUs vested immediately upon grant on November 7, 2024; there was no expiration date for the RSUs.

SEC source: 0001415889-24-026617 · form4-11122024_091100.xml · derivative · entry 2

Levy Richard S · CIK 0001454983 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,303

Underlying: Class A Ordinary Shares · 1,303 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

F2 · derivative.exercise_date: The RSUs vested immediately upon grant on November 7, 2024; there was no expiration date for the RSUs.

F2 · derivative.expiration_date: The RSUs vested immediately upon grant on November 7, 2024; there was no expiration date for the RSUs.

SEC source: 0001415889-24-026617 · form4-11122024_091100.xml · nonDerivative · entry 1

Levy Richard S · CIK 0001454983 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,200

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

SEC source: 0001415889-24-026451 · form4-11082024_091109.xml · derivative · entry 4

Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,025

Underlying: Class A Ordinary Share · 89,561 shares

Expires 2025-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024.

F3 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001415889-24-026451 · form4-11082024_091109.xml · nonDerivative · entry 2

Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 79,551

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024.

F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $23.00 and $23.12. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001415889-24-026451 · form4-11082024_091109.xml · nonDerivative · entry 1

Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 169,112

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024.

SEC source: 0001415889-24-025374 · form4-10172024_081035.xml · derivative · entry 3

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,017

Underlying: Class A Ordinary Share · 10,000 shares

Expires 2025-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.

F3 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001415889-24-025374 · form4-10172024_081035.xml · nonDerivative · entry 2

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 109,975

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.

F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $26.465 and $27.15. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001415889-24-025374 · form4-10172024_081035.xml · nonDerivative · entry 1

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 126,975

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.

SEC source: 0000950170-24-113535 · ownership.xml · derivative · entry 6

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 28,384

Underlying: Class A ordinary shares · 28,384 shares

Expires 2034-10-03

F14 · shares: On October 4, 2024, the Issuer granted 28,384 Share Options to M. Cantey Boyd, pursuant to the Incentive Award Plan. The Share Options have a strike price of $24.48, one third of which vests on the first anniversary of the grant date with the remaining two thirds vesting in 24 equal monthly installments, and expire 10 years from the date of grant.

F14 · derivative.exercise_date: On October 4, 2024, the Issuer granted 28,384 Share Options to M. Cantey Boyd, pursuant to the Incentive Award Plan. The Share Options have a strike price of $24.48, one third of which vests on the first anniversary of the grant date with the remaining two thirds vesting in 24 equal monthly installments, and expire 10 years from the date of grant.

F5 · ownership.nature: Pursuant to the policies of the Adviser, Felix J. Baker, Dr. Biggar and M. Cantey Boyd do not have a right to any of the Issuer's securities issued as compensation for their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified share options exercisable solely into Class A ordinary shares ("Share Options") and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Share Options, RSUs and any Class A ordinary shares acquired upon the exercise of Share Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F6 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F7 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F8 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options, RSUs and any Class A ordinary shares received as a result of the exercise of Share Options or vesting of RSUs.

F9 · ownership.nature: The acquisitions of the RSUs and Share Options reported on this form represent grants to M. Cantey Boyd of 4,730 RSUs on Table I and 28,384 Share Options on Table II. These grants, totaling 4,730 RSUs and 28,384 Share Options for M. Cantey Boyd, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F12 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Class A ordinary shares reported in column 5 of Table I and the Share Options reported in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0000950170-24-113535 · ownership.xml · derivative · entry 5

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 28,384

Underlying: Class A ordinary shares · 28,384 shares

Expires 2034-10-03

F14 · shares: On October 4, 2024, the Issuer granted 28,384 Share Options to M. Cantey Boyd, pursuant to the Incentive Award Plan. The Share Options have a strike price of $24.48, one third of which vests on the first anniversary of the grant date with the remaining two thirds vesting in 24 equal monthly installments, and expire 10 years from the date of grant.

F14 · derivative.exercise_date: On October 4, 2024, the Issuer granted 28,384 Share Options to M. Cantey Boyd, pursuant to the Incentive Award Plan. The Share Options have a strike price of $24.48, one third of which vests on the first anniversary of the grant date with the remaining two thirds vesting in 24 equal monthly installments, and expire 10 years from the date of grant.

F4 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Class A ordinary shares reported in column 5 of Table I and the Share Options (as defined below) reported in column 9 of Table II held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F5 · ownership.nature: Pursuant to the policies of the Adviser, Felix J. Baker, Dr. Biggar and M. Cantey Boyd do not have a right to any of the Issuer's securities issued as compensation for their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified share options exercisable solely into Class A ordinary shares ("Share Options") and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Share Options, RSUs and any Class A ordinary shares acquired upon the exercise of Share Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F6 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F7 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F8 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options, RSUs and any Class A ordinary shares received as a result of the exercise of Share Options or vesting of RSUs.

F9 · ownership.nature: The acquisitions of the RSUs and Share Options reported on this form represent grants to M. Cantey Boyd of 4,730 RSUs on Table I and 28,384 Share Options on Table II. These grants, totaling 4,730 RSUs and 28,384 Share Options for M. Cantey Boyd, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

SEC source: 0000950170-24-113535 · ownership.xml · nonDerivative · entry 2

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,730,419

F1 · shares: On October 4, 2024, Kiniksa Pharmaceuticals International, plc (the "Issuer") granted 4,730 restricted share units (each an "RSU") payable solely in Class A ordinary shares ("Class A ordinary shares") to M. Cantey Boyd, a full-time employee of Baker Bros. Advisors LP (the "Adviser"), in conjunction with her appointment to the board of directors of the Issuer (the "Board") pursuant to the Issuer's 2018 Incentive Award Plan (the "Incentive Award Plan"). One third of the RSUs vest on each anniversary of the grant date subject to M. Cantey Boyd's continuous service on the Board through the vesting date. Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP"), and M. Cantey Boyd and Dr. Stephen Biggar, full-time employees of the Adviser, serve on the Board as representatives of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

F2 · balance_after: On June 27, 2024, Kiniksa Pharmaceuticals, Ltd. ("Old Kinksa") consummated redomiciliation transactions that resulted in the Issuer becoming the successor issuer to Old Kiniksa (the "Redomiciliation"). Pursuant to the Redomiciliation, holders of Old Kiniksa securities received (i) one Class A ordinary share of the Issuer for each Class A common share of Old Kiniksa held immediately prior to the effectiveness of the Redomiciliation; (ii) one Class A1 ordinary share of the Issuer for each Class A1 common share of Old Kiniksa held immediately prior to the effectiveness of the Redomiciliation; (continued in Footnote 3)

F3 · balance_after: (continued from footnote 2) (iii) one Class B ordinary share of the Issuer for each Class B common share of Old Kiniksa held immediately prior to the effectiveness of the Redomiciliation; and (iv) one Class B1 ordinary share of the Issuer for each Class B1 common share of Old Kiniksa held immediately prior to the effectiveness of the Redomiciliation, with no change in economic interest for any such holders as a result of the Redomiciliation.

F5 · ownership.nature: Pursuant to the policies of the Adviser, Felix J. Baker, Dr. Biggar and M. Cantey Boyd do not have a right to any of the Issuer's securities issued as compensation for their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified share options exercisable solely into Class A ordinary shares ("Share Options") and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Share Options, RSUs and any Class A ordinary shares acquired upon the exercise of Share Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F6 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F7 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F8 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options, RSUs and any Class A ordinary shares received as a result of the exercise of Share Options or vesting of RSUs.

F9 · ownership.nature: The acquisitions of the RSUs and Share Options reported on this form represent grants to M. Cantey Boyd of 4,730 RSUs on Table I and 28,384 Share Options on Table II. These grants, totaling 4,730 RSUs and 28,384 Share Options for M. Cantey Boyd, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F10 · ownership.nature: Includes beneficial ownership of 12,546 Class A ordinary shares received or to be received from vesting of RSUs each previously granted to Felix J. Baker and Dr. Biggar in their capacity as directors of the Issuer.

F12 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Class A ordinary shares reported in column 5 of Table I and the Share Options reported in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0000950170-24-113535 · ownership.xml · nonDerivative · entry 1

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 128,802

F1 · shares: On October 4, 2024, Kiniksa Pharmaceuticals International, plc (the "Issuer") granted 4,730 restricted share units (each an "RSU") payable solely in Class A ordinary shares ("Class A ordinary shares") to M. Cantey Boyd, a full-time employee of Baker Bros. Advisors LP (the "Adviser"), in conjunction with her appointment to the board of directors of the Issuer (the "Board") pursuant to the Issuer's 2018 Incentive Award Plan (the "Incentive Award Plan"). One third of the RSUs vest on each anniversary of the grant date subject to M. Cantey Boyd's continuous service on the Board through the vesting date. Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP"), and M. Cantey Boyd and Dr. Stephen Biggar, full-time employees of the Adviser, serve on the Board as representatives of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

F2 · balance_after: On June 27, 2024, Kiniksa Pharmaceuticals, Ltd. ("Old Kinksa") consummated redomiciliation transactions that resulted in the Issuer becoming the successor issuer to Old Kiniksa (the "Redomiciliation"). Pursuant to the Redomiciliation, holders of Old Kiniksa securities received (i) one Class A ordinary share of the Issuer for each Class A common share of Old Kiniksa held immediately prior to the effectiveness of the Redomiciliation; (ii) one Class A1 ordinary share of the Issuer for each Class A1 common share of Old Kiniksa held immediately prior to the effectiveness of the Redomiciliation; (continued in Footnote 3)

F3 · balance_after: (continued from footnote 2) (iii) one Class B ordinary share of the Issuer for each Class B common share of Old Kiniksa held immediately prior to the effectiveness of the Redomiciliation; and (iv) one Class B1 ordinary share of the Issuer for each Class B1 common share of Old Kiniksa held immediately prior to the effectiveness of the Redomiciliation, with no change in economic interest for any such holders as a result of the Redomiciliation.

F4 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Class A ordinary shares reported in column 5 of Table I and the Share Options (as defined below) reported in column 9 of Table II held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F5 · ownership.nature: Pursuant to the policies of the Adviser, Felix J. Baker, Dr. Biggar and M. Cantey Boyd do not have a right to any of the Issuer's securities issued as compensation for their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified share options exercisable solely into Class A ordinary shares ("Share Options") and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Share Options, RSUs and any Class A ordinary shares acquired upon the exercise of Share Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F6 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F7 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F8 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options, RSUs and any Class A ordinary shares received as a result of the exercise of Share Options or vesting of RSUs.

F9 · ownership.nature: The acquisitions of the RSUs and Share Options reported on this form represent grants to M. Cantey Boyd of 4,730 RSUs on Table I and 28,384 Share Options on Table II. These grants, totaling 4,730 RSUs and 28,384 Share Options for M. Cantey Boyd, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F10 · ownership.nature: Includes beneficial ownership of 12,546 Class A ordinary shares received or to be received from vesting of RSUs each previously granted to Felix J. Baker and Dr. Biggar in their capacity as directors of the Issuer.

SEC source: 0001415889-24-024885 · form4-10082024_081027.xml · derivative · entry 3

Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175

Underlying: Class A Ordinary Share · 175 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

F2 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each anniversary of the date of grant, October 4, 2021.

F2 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each anniversary of the date of grant, October 4, 2021.

SEC source: 0001415889-24-024885 · form4-10082024_081027.xml · nonDerivative · entry 2

Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,528

SEC source: 0001415889-24-024885 · form4-10082024_081027.xml · nonDerivative · entry 1

Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,610

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

SEC source: 0001415889-24-023954 · form4-09252024_080916.xml · derivative · entry 3

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,017

Underlying: Class A Ordinary Share · 10,000 shares

Expires 2025-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.

F3 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001415889-24-023954 · form4-09252024_080916.xml · nonDerivative · entry 2

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 116,975

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.

F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $24.62 and $25.60. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001415889-24-023954 · form4-09252024_080916.xml · nonDerivative · entry 1

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 134,475

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.

SEC source: 0001415889-24-022856 · form4-09052024_120908.xml · derivative · entry 15

Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,549

Underlying: Class A Ordinary Share · 475 shares

Expires 2027-06-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2024.

F10 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001415889-24-022856 · form4-09052024_120908.xml · derivative · entry 14

Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Ordinary Share · 60,217 shares

Expires 2026-09-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2024.

F10 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001415889-24-022856 · form4-09052024_120908.xml · nonDerivative · entry 8

Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 52,038

F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2024.

F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $26.995 to $27.18. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001415889-24-022856 · form4-09052024_120908.xml · nonDerivative · entry 7

Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 53,516

F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2024.

F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $25.88 to $26.82. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001415889-24-022856 · form4-09052024_120908.xml · nonDerivative · entry 6

Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 112,730

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2024.

SEC source: 0001415889-24-022856 · form4-09052024_120908.xml · nonDerivative · entry 5

Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 112,255

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2024.

SEC source: 0001415889-24-022854 · form4-09052024_120928.xml · derivative · entry 18

Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,924

Underlying: Class A Ordinary Share · 24,776 shares

Expires 2032-08-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 3, 2024

F13 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2022.